Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Novartis Pharma Services AG
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A Phase III, Open Label, Randomized Trial of Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Subjects with Relapsed Chronic Lymphocytic Leukemia (COMPLEMENT 2 STUDY)
The primary objective is to evaluate progression free survival of combination ofatumumab-fludarabine-cyclophosphamide therapy vs. fludarabine-cyclophosphamide therapy for the treatment of relapsed CLL...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A double-blind, randomized, multicenter, parallel group study to evaluate the efficacy, tolerability, and safety of treatment with the combination of valsartan/amlodipine 160/5 mg compared to amlodipine 10 mg in patients with essential hypertension not adequately controlled with amlodipine 5 mg alone
To confirm that the combination of valsartan/amlodipine 160/5mg is non-inferior to amlodipine 10mg alone when comparing the reduction of MSSBP from baseline to week 8 (Visit 4) between the two treatme...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
An open-label clinical trial that compares how long it takes in total for a patient with cystic fibrosis to take a daily dose of tobramycin dry power versus nebulised forms of tobramycin or colistin
To compare as a primary indicator for ease of use the mean cumulative time required to set-up the delivery device (including preparation of the treatment), administer the drug, and clean the delivery ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A 3-year follow-up study in chronic hepatitis C patients who failed to achieve sustained virologic response during Novartis-sponsored alisporivir studies
To determine the persistence of resistance associated variants associated with failure to previous alisporivir therapy.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A study to check how safe, beneficial and tolerable the drug canakinumab is for patients with NOMID / CINCA syndrome
This study will examine whether a medicine called canakinumab is safe and effective for treating patients with neonatal-onset multisystem inflammatory disease (NOMID), also known as chronic infantile...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
Efficacy, safety and tolerability of multiple doses of valsartan in children with hypertension with or without chronic kidney disease
To evaluate if a dose dependent reduction in MSBP exists when comparing two doses of valsartan solution over a 6wk period in children 1-5 years old with hypertension with or without CKD.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A phase II study of re-treatment of myelofibrosis patients with ruxolitinib/Jakavi after treatment interruption due to loss of response and/or adverse event
To evaluate the effect of re-treatment with ruxolitinib on reduction in spleen volume of at least 20% from baseline, by Week 24
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A randomized, double-masked, multicenter, laser-controlled Phase III study assessing the efficacy and safety of ranibizumab (intravitreal injections) as adjunctive and mono-therapy in patients with visual impairment due to diabetic macular edema
The primary objective of this study is to demonstrate superiority of ranibizumab 0.5 mg as adjunctive or mono-therapy to laser treatment in the mean change from baseline in BCVA over a 12-month treatm...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A study to evaluate the effects of AMG334 compared to placebo medication in the prophylactic treatment of migraine in adult patients who have already tried other prophylactic migraine treatments unsuccessfully
To evaluate the effect of AMG 334 compared to placebo on the proportion of patients with at least 50% reduction from baseline in monthly migraine days
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A 12 week, double-blind, randomized, parallel group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren 300 mg and hydrochlorothiazide 25 mg compared to aliskiren 300 mg in patients with Stage II hypertension
To compare the BP lowering effect of the combination of aliskiren / HCTZ 300/25 mg versus aliskiren 300 mg monotherapy in patients with Stage II hypertension by testing the hypothesis that the combina...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
18
19
20
21
22
23
24
25
26
27
Suivant